CTIS2023-506368-14-00招募中1 期
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus - SL0046
CB Biopharma0 个研究点目标入组 760 人开始时间: 2023年10月24日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 760
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment - The participant completed one of the placebo controlled (PBO-controlled) parent studies within 4 weeks prior to entry to this study
排除标准
- •- Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant’s ability to participate in this study. This includes study participants with a life-threatening condition or ongoing malignancies at the start of the study
研究者
相似试验
招募中
1 期
A Study to evaluate the safety and tolerability of dapirolizumab pegol in study participants with systemic lupus erythematosusSystemic lupus erythematosusEUCTR2019-003409-83-ITCB Biopharma SR760
进行中（未招募）
1 期
An extension study to learn if Bimekizumab works and is safe over a long period in adults with Active Axial Spondyloarthritis.Axial SpondyloarthritisMedDRA version: 21.1Level: PTClassification code: 10071400Term: Axial spondyloarthritis Class: 100000004859CTIS2023-506527-28-00CB Biopharma691
已完成
3 期
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisPsoriatic ArthritisJPRN-jRCT2080224964CB Japan Co., Ltd30
进行中（未招募）
1 期
A Study to evaluate the safety and tolerability of dapirolizumab pegol in study participants with systemic lupus erythematosusSystemic lupus erythematosusEUCTR2019-003409-83-PLCB Biopharma SR760
进行中（未招募）
1 期
A Study to evaluate the safety and tolerability of dapirolizumab pegol in study participants with systemic lupus erythematosusSystemic lupus erythematosusEUCTR2019-003409-83-BECB Biopharma SR760